Contineum Therapeutics (CTNM) Interest & Investment Income (2023 - 2026)

Contineum Therapeutics' Interest & Investment Income history runs 4 years deep, the most recent figure standing at $2.5 million for Q1 2026.

• On a quarterly basis, Interest & Investment Income rose 11.33% year-over-year to $2.5 million in Q1 2026; TTM through Mar 2026 was -$3.4 million, a 177.78% decrease from a year earlier, with the FY2025 full-year figure at $189000.0, up 610.81% from the prior year.
• Interest & Investment Income climbed to $2.5 million in Q1 2026 per CTNM's latest filing, from -$6.0 million in the prior quarter.
• Across five years, Interest & Investment Income topped out at $4.6 million in Q4 2023 and bottomed at -$6.0 million in Q4 2025.
• The 4-year median for Interest & Investment Income is -$23000.0 (2025), against an average of $417307.7.
• Across the five-year window, Interest & Investment Income soared 11520.83% in 2024 and slumped 1134.08% in 2025, its largest moves.
• Year by year, Interest & Investment Income stood at $4.6 million in 2023, then slumped by 110.61% to -$490000.0 in 2024, then slumped by 1134.08% to -$6.0 million in 2025, then jumped by 141.43% to $2.5 million in 2026.
• Per Business Quant, the three latest CTNM Interest & Investment Income figures stand at $2.5 million (Q1 2026), -$6.0 million (Q4 2025), and $118000.0 (Q3 2025).